TABLE II -.

Effects of different statins on primary failure of arteriovenous fistulas adjusting for clinical covariates^a

	All statinsb	Atorvastatin	Rosuvastatin	Simvastatin
All fistulas
No. on statins/no statins	238/297	39/297	126/297	58/297
Median statin dose (mg; IQR)	NA	20 (20–40)	10 (10–15)	20 (20–40)
Odds ratio	0.63	0.18	0.61	1.29
95% confidence interval	0.40–0.99	0.06–0.60	0.34–1.08	0.66–2.52
p value	0.046	0.005	0.087	0.45
One-stage fistulas
No. on statins/no statins	98/132	17/132	54/132	19/132
Median statin dose (mg; IQR)	NA	40 (20–40)c	10 (10–20)	20 (10–40)
Odds ratio	0.45	0.03	0.43	0.94
95% confidence interval	0.21–0.94	0.002–0.35	0.17–1.12	0.27–3.36
p value	0.034	0.005	0.085	0.93
Two-stage fistulas
No. on statins/no statins	140/165	22/165	72/165	39/165
Median statin dose (mg; IQR)	NA	20 (10–20)c	10 (5–10)	20 (20–40)
Odds ratio	0.79	0.43	0.79	1.59
95% confidence interval	0.44–1.43	0.10–1.81	0.37–1.68	0.70–3.61
p value	0.44	0.25	0.55	0.27

IQR = interquartile range.

^aPatients in the indicated treatment groups were compared to those on no statins using multivariate logistic regressions adjusted for age, sex, ethnicity, coronary artery disease, congestive heart failure, diabetes, antiplatelet agents, angiotensin converting enzyme inhibitor/angiotensin II receptor blocker, prior catheter use, and history of previous AVF.

^bThe All Statins group includes patients on atorvastatin, rosuvastatin, simvastatin, lovastatin, and pravastatin (see Supplementary Tab. S1, available online as Supplementary material at www.vascular-access.info).

^cThe difference in the atorvastatin daily dose between one-stage and two-stage patients is not statistically significant (Mann-Whitney U-test; p = 0.088).